Phase 3 Study of Selpercatinib Meets Primary PFS End Point in NSCLC

Patients with RET fusion-positive advanced or metastatic non–small cell lung cancer had a survival benefit when treated with selpercatinib in the LIBRETTO-431 study.

Related Keywords

Eli Lilly ,David Hyman ,Selpercatinib Retevmo ,Lung Cancer ,Non Small Cell Lung Cancer ,Nsclc ,Selpercatinib ,Ret Fusion Positive Advanced ,Metastatic ,Libretto 431 ,